Partner David Rosen was quoted in a Modern Healthcare article, “Federal investigation finds holes in orphan drug approval process,” about an investigation by federal regulators that found fault with the U.S. Food and Drug Administration’s process for approving so-called orphan drugs.
While the report suggests there may be holes in the agency’s documentation process, Rosen said, that doesn’t mean that FDA reviewers aren’t weighing the impact of a drug’s regulatory or marketing history. “The fact that maybe all the i’s aren’t dotted or t’s aren’t crossed is a technical claim, but whether it has a true material bearing is another story,” he said.
While the report suggests there may be holes in the agency’s documentation process, Rosen said, that doesn’t mean that FDA reviewers aren’t weighing the impact of a drug’s regulatory or marketing history. “The fact that maybe all the i’s aren’t dotted or t’s aren’t crossed is a technical claim, but whether it has a true material bearing is another story,” he said.
People
Related News
03 May 2024
In the News
Jeff Symons’ Move to Foley Featured in Press
Foley & Lardner LLP partner Jeff Symons is featured in legal press for his recent arrival to the firm
03 May 2024
In the News
Nathaniel Lacktman on Healthleaders Podcast– ‘We’re seeing maturity in the telemedicine market’
Foley & Lardner LLP partner Nathaniel Lacktman discussed the upcoming American Telemedicine Association’s annual conference, new developments in telemedicine and digital health, the regulatory context, and the prospects for the industry’s future
02 May 2024
In the News
Jennifer Hennessy on American Privacy Rights Act – ‘This law does have teeth’
Foley & Lardner LLP partner Jennifer Hennessy assesses the prospects of what could be the first federal data privacy law passed in the United States